AVTR · Insider Trading
Avantor, Inc.
Every open-market purchase and sale reported by AVTR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-23 | Todd W Garner | EVP and CFO | A | +49,688 | — |
| 2026-08-20 | Emmanuel Ligner | President and CEO | F | −29,803 | −$397.27K |
| 2026-08-18 | Brittany Hankamer | EVP, Chief HR Officer | F | −181 | −$2.47K |
| 2026-08-04 | Steven W Eck | SVP & Chief Accounting Officer | F | −1,385 | −$19.09K |
| 2026-07-27 | Claudius Sokenu | EVP, Chief Legal & Compliance | F | −1,201 | −$13.74K |
| 2026-06-22 | Corey Walker | President, VWR Dist. & Servs. | F | −3,010 | −$28.84K |
| 2026-05-11 | Gregory L Summe | Director | A | +25,270 | — |
| 2026-05-11 | Michael Severino | Director | A | +25,270 | — |
| 2026-05-11 | Sanjeev K Mehra | Director | A | +25,270 | — |
| 2026-05-11 | Joseph R Massaro | Director | A | +25,270 | — |
| 2026-05-11 | Louise Makin | Director | A | +25,270 | — |
| 2026-05-11 | Simon Dingemans | Director | A | +25,270 | — |
| 2026-05-11 | Gregory T Lucier | Director | MIXED | +35,270 | +$83.20K |
| 2026-05-11 | Mala Murthy | Director | A | +25,270 | — |
| 2026-05-05 | Ludovic Brellier | EVP, Bioscience & Medtech | A | +146,566 | — |
| 2026-05-05 | Simon Dingemans | Director | Buy | +25,000 | +$203.50K |
| 2026-04-06 | Steven W Eck | SVP & Chief Accounting Officer | A | +31,645 | — |
| 2026-03-11 | Sanjeev K Mehra | Director | Buy | +125,000 | +$1.00M |
| 2026-02-25 | Steven W Eck | SVP & Chief Accounting Officer | F | −2,469 | −$22.05K |
| 2026-02-25 | Benoit Gourdier | EVP, Bioscience & Medtech | F | −3,029 | −$26.93K |
| 2026-02-25 | R. Brent Jones | EVP, Chief Financial Officer | F | −2,805 | −$24.94K |
| 2026-02-25 | Brittany Hankamer | EVP, Chief HR Officer | F | −1,683 | −$15.04K |
| 2026-02-25 | Claudius Sokenu | EVP, Chief Legal & Compliance | F | −2,376 | −$21.12K |
| 2026-02-23 | R. Brent Jones | EVP, Chief Financial Officer | MIXED | +151,731 | −$85.84K |
| 2026-02-23 | Benoit Gourdier | EVP, Bioscience & Medtech | MIXED | +130,204 | −$37.56K |
| 2026-02-23 | Claudius Sokenu | EVP, Chief Legal & Compliance | MIXED | +77,699 | −$26.36K |
| 2026-02-23 | Corey Walker | President, VWR Dist. & Servs. | MIXED | +156,274 | −$44.82K |
| 2026-02-23 | Emmanuel Ligner | President and CEO | A | +483,713 | — |
| 2026-02-23 | Steven W Eck | SVP & Chief Accounting Officer | MIXED | +46,734 | −$19.19K |
| 2026-02-23 | Mary Blenn | EVP, Chief Operating Officer | A | +235,993 | — |
| 2026-02-23 | Gregory T Lucier | Director | Buy | +50,000 | +$458.00K |
| 2026-02-23 | Brittany Hankamer | EVP, Chief HR Officer | MIXED | +79,165 | −$13.12K |
| 2026-02-12 | Gregory L Summe | Director | Buy | +100,000 | +$940.00K |
| 2026-01-12 | Simon Dingemans | Director | A | +6,225 | — |
| 2025-12-09 | Sanjeev K Mehra | Director | MIXED | +358,106 | +$3.88M |
| 2025-11-17 | Emmanuel Ligner | President and CEO | Buy | +87,500 | +$993.12K |
| 2025-11-12 | Mary Blenn | EVP, Chief Operating Officer | A | +17,391 | — |
| 2025-10-31 | Gregory L Summe | Director | Buy | +100,000 | +$1.12M |
| 2025-10-07 | Gregory T Lucier | Director | A | +8,736 | — |
| 2025-10-03 | Benoit Gourdier | EVP, Bioscience Production | F | −1,264 | −$17.41K |
| 2025-08-22 | Gregory L Summe | Director | Buy | +100,000 | +$1.26M |
| 2025-08-21 | Emmanuel Ligner | President and CEO | A | +195,924 | — |
| 2025-08-15 | Brittany Hankamer | EVP, Chief HR Officer | F | −181 | −$2.35K |
| 2025-08-12 | Christophe Couturier | EVP, AMEA | A | +65,217 | — |
| 2025-08-06 | Steven W Eck | SVP & Chief Accounting Officer | Sell | −3,476 | −$39.59K |
| 2025-08-04 | Steven W Eck | SVP & Chief Accounting Officer | F | −1,385 | −$18.61K |
| 2025-07-25 | Claudius Sokenu | EVP, Chief Legal & Compliance | F | −3,123 | −$43.75K |
| 2025-06-24 | Corey Walker | President Laboratory Solutions | F | −2,730 | −$37.05K |
| 2025-05-27 | Gregory L Summe | Director | Buy | +30,000 | +$375.00K |
| 2025-05-22 | Gregory L Summe | Director | Buy | +20,000 | +$253.00K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Michael Stubblefield | President & CEO | 1,764,513 | $28.87M |
| Emmanuel Ligner | President and CEO | 737,334 | $12.06M |
| Sanjeev K Mehra | Director | 508,376 | $8.32M |
| Gregory L Summe | Director | 483,381 | $7.91M |
| R. Brent Jones | EVP, Chief Financial Officer | 419,782 | $6.87M |
| Corey Walker | President, VWR Dist. & Servs. | 384,535 | $6.29M |
| Benoit Gourdier | EVP, Bioscience & Medtech | 362,859 | $5.94M |
| Mary Blenn | EVP, Chief Operating Officer | 253,384 | $4.15M |
| Claudius Sokenu | EVP, Chief Legal & Compliance | 251,228 | $4.11M |
| Brittany Hankamer | EVP, Chief HR Officer | 248,864 | $4.07M |
| Jonathan M Peacock | Director | 219,815 | $3.60M |
| Christophe Couturier | EVP, AMEA | 211,271 | $3.46M |
| Ludovic Brellier | EVP, Bioscience & Medtech | 146,566 | $2.40M |
| Steven W Eck | SVP & Chief Accounting Officer | 129,593 | $2.12M |
| Gregory T Lucier | Director | 94,006 | $1.54M |
| James Bramwell | EVP Sales, Customer Excellence | 86,605 | $1.42M |
| Michael Severino | Director | 85,821 | $1.40M |
| Joseph R Massaro | Director | 77,408 | $1.27M |
| Mala Murthy | Director | 69,479 | $1.14M |
| Juan Andres | Director | 65,480 | $1.07M |
| Simon Dingemans | Director | 56,495 | $924.26K |
| Lan Kang | Director | 52,315 | $855.87K |
| Todd W Garner | EVP and CFO | 49,688 | $812.90K |
| Louise Makin | Director | 47,140 | $771.21K |
| John Carethers | Director | 45,858 | $750.24K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AVTR quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.